Clinical Trials Browser

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT03317158 2026-04-15

ADAPT-BLADDER

Phase 1/2 Recruiting

55 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05483868 2026-04-15

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Phase 1 Recruiting

55 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03528694 2026-04-14

POTOMAC

Phase 3 Active not recruiting

1,018 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05316155 2026-04-13

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Phase 1/2 Recruiting

235 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06211764 2026-04-13

SunRISe-5

Phase 3 Active not recruiting

272 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06319820 2026-04-13

MoonRISe-1

Phase 3 Recruiting

641 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06995677 2026-04-09

SURF302

Phase 2 Recruiting

90 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06503614 2026-04-08

ENHANCE

Phase 2 Recruiting

60 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07000084 2026-04-07

GAIN-BCG

Phase 3 Recruiting

330 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07206225 2026-04-07

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Phase 1 Recruiting

294 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06833073 2026-04-06

INTerpath-011

Phase 2 Recruiting

308 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT05538663 2026-04-03

BRIDGE

Phase 3 Active not recruiting

870 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06253845 2026-04-01

Study of CG0070 After Transurethral Resection in Patients With IR NMIBC

Phase 1 Active not recruiting

20 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07505615 2026-04-01

VG-INFUSE Tria

Phase 1/2 Completed

20 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT02138734 2026-03-31

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Phase 1/2 Active not recruiting

369 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT06704191 2026-03-30

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Phase 1/2 Recruiting

40 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06800963 2026-03-27

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

Phase 1/2 Recruiting

40 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07495072 2026-03-27

PRO-GAG

Phase NA Recruiting

56 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Cystitis, Interstitial

Clinical Trials

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

ADAPT-BLADDER

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

POTOMAC

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

SunRISe-5

MoonRISe-1

SURF302

ENHANCE

GAIN-BCG

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

INTerpath-011

BRIDGE

Study of CG0070 After Transurethral Resection in Patients With IR NMIBC

VG-INFUSE Tria

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

PRO-GAG